Myelofibrosis Treatment Market By Product Type (Ruxolitinib, Fedratinib, Pacritinib, Momelotinib, Other and Emerging Therapies); By Treatment Application (Anaemic Myelofibrosis, Severe Thrombocytopenic Myelofibrosis, JAK-Inhibitor-Naïve Myelofibrosis, Relapsed or Refractory Myelofibrosis); By End User (Hospitals, Haematology and Oncology Clinics, Specialty Treatment Centres, Homecare Settings); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Myelofibrosis Treatment Market: Cytopenia-Focused Therapies Reshape Revenue, Competition and Patient Access

The Global Myelofibrosis Treatment Market was valued at USD 3.45 billion in 2025 and is to reach USD 6.03 billion by 2032, expanding at a CAGR of 8.3% during 2026–2032, according to Strategic Market Research.

 

Myelofibrosis treatment currently includes four FDA-approved JAK inhibitors: ruxolitinib for frontline symptom and spleen control, fedratinib for first-line or post-ruxolitinib use, pacritinib for patients with severe thrombocytopenia, and momelotinib for those with moderate-to-severe anaemia. The R&D pipeline is moving towards targeted agents and combination strategies intended to improve anaemia, reduce marrow fibrosis, overcome resistance and potentially alter the disease course. These differences have made the market increasingly segmented by blood count, prior treatment and persistence rather than by broad disease diagnosis alone.

 

From Diagnosis to Refill: Where Market Revenue Is Won or Lost

A claims-based analysis estimated that the United States had approximately 21,133 people with myelofibrosis in 2023, equivalent to 6.3 patients per 100,000 people. Cytopenic myelofibrosis accounted for an estimated 4.5 patients per 100,000, showing that anaemia and low platelet counts affect a large share of the commercially relevant population. Transplantation remains the only potentially curative option, but only 69 patients, or 4.5%, in a recent 1,532-patient U.S. claims cohort underwent haematopoietic stem-cell transplantation. The main revenue stream therefore comes from prescriptions and refills maintained over months or years.

The diagnosed population does not translate directly into treated demand. Lower-risk or asymptomatic patients may remain under observation, while blood counts, disease risk, previous therapy and insurance conditions can restrict treatment initiation. In a U.S. claims study of 1,191 eligible patients, 60% received at least one captured line of therapy. Among treated patients, 46% received two or more lines, confirming that switching and subsequent-line treatment form a meaningful part of commercial demand.

Treatment duration is especially important because the market is measured in recurring patient-months. A commercial-claims analysis of 481 ruxolitinib-treated patients found that 257, or 53.4%, had anaemia before starting treatment. Median time to discontinuation was 14.1 months among patients with anaemia, compared with 23.8 months among those without anaemia. At one year, 47.6% of the anaemic group had discontinued treatment, versus 31.6% of patients without anaemia.

This shorter persistence creates two commercial effects. It reduces the length of revenue generated by the first treatment and expands the pool of patients requiring another option. Therapies able to maintain blood counts, reduce transfusion dependence or retain patients after ruxolitinib therefore compete for both newly diagnosed demand and treatment-switching demand.

The same analysis reported annual JAK-inhibitor pharmacy costs of approximately USD 122,283 for patients with anaemia and USD 135,752 for those without anaemia, measured in 2022 dollars. High recurring expenditure increases payer scrutiny, but it also raises the commercial value of longer treatment duration and successful reimbursement.

Hospital utilisation adds further economic pressure. In the 1,191-patient claims cohort, all-cause costs increased from USD 24,216 in the six months before the index diagnosis to USD 48,966 in the following six months. Myelofibrosis-related costs rose from USD 16,502 to USD 39,383. Inpatient care and pharmacy spending were major contributors, strengthening the payer case for treatments that reduce complications, transfusion requirements or hospital use.

 

Blood Counts Are Redrawing the Commercial Treatment Map

Ruxolitinib, marketed as Jakafi in the United States and Jakavi in several international markets, retains the broadest established position. Specialist familiarity, reimbursement coverage and an established specialty-pharmacy channel support its continued use in intermediate- or high-risk primary and secondary myelofibrosis. However, worsening anaemia, thrombocytopenia, intolerance and loss of response can restrict dosing or shorten treatment duration.

Fedratinib provides another JAK-inhibitor option for adults with intermediate-2 or high-risk disease, including patients previously treated with ruxolitinib. It competes for patients who are unsuitable for the incumbent and those requiring another JAK-based therapy after progression or intolerance. Its U.S. orphan exclusivity is scheduled to end on 16 August 2026, which may increase payer and competitive attention, although future generic entry will also depend on patent coverage and regulatory filings.

Pacritinib established a specific U.S. treatment position for patients with platelet counts below 50,000 per microlitre. These patients were difficult to treat with earlier therapies because severe thrombocytopenia can restrict JAK-inhibitor dosing. The label gives Sobi a clear clinical niche, but the eligible patient pool is considerably narrower than the broader anaemia-defined population.

Momelotinib has altered competitive positioning by addressing intermediate- or high-risk myelofibrosis with anaemia. Its activity against JAK1, JAK2 and ACVR1 allows it to compete around spleen control, symptoms and anaemia-related treatment needs. The product can be used in eligible JAK-inhibitor-naïve patients and in those previously treated with ruxolitinib, giving GSK access to both first-line and switching opportunities.

 

The Incumbent Franchise Still Sets the Revenue Benchmark

Incyte reported second-quarter 2026 total revenue of USD 1.67 billion, representing a 38% increase from the prior-year period. Jakafi and Jakafi XR generated USD 817 million in net sales, up 7%, while paid patient demand increased across approved indications. Full-year 2026 Jakafi guidance remained between USD 3.22 billion and USD 3.27 billion.

Jakafi revenue includes polycythaemia vera and graft-versus-host disease as well as myelofibrosis, so the reported figure cannot be treated as myelofibrosis-only sales. It nevertheless demonstrates the scale of Incyte’s specialist-prescriber network, pharmacy distribution and reimbursement position.

Incyte introduced Jakafi XR in May 2026 as a once-daily extended-release formulation. The launch gives the company an additional lifecycle-management tool as newer therapies compete for patients with cytopenias or declining response. Its commercial impact will depend on prescriber uptake and whether simplified dosing supports measurable persistence.

GSK has achieved the strongest recent product-level momentum in the anaemia-defined segment. Ojjaara and Omjjara generated £554 million in 2025, increasing 57% on a reported basis and 60% at constant exchange rates. U.S. growth was mainly volume-driven, while launches in France, Spain, Italy, Australia and Canada expanded the product’s geographic reach. By the end of 2025, the treatment was available in more than 30 countries.

The product’s growth confirms that anaemia is becoming a major revenue pool within myelofibrosis treatment. Momelotinib can capture patients at treatment initiation and after ruxolitinib discontinuation, while its international growth depends on national reimbursement decisions rather than regulatory approval alone.

 

A Narrow Platelet Segment Tests the Limits of Differentiation

Sobi’s Vonjo performance demonstrates that a distinct clinical position does not guarantee sustained revenue expansion. Fourth-quarter 2025 sales declined to SEK 327 million from SEK 416 million a year earlier, while full-year revenue fell to SEK 1.242 billion from SEK 1.462 billion. Underlying demand was offset by gross-to-net adjustments, destocking and competitive pressure.

Sobi also recorded a SEK 6.612 billion impairment against Vonjo’s product and marketing rights. The company connected the impairment to competition in the United States, limited growth within the platelet-below-50,000 label and reimbursement pressure.

Pacritinib remains important for patients with severe thrombocytopenia, but the product’s commercial ceiling is shaped by the smaller eligible population and high payer sensitivity. Its performance contrasts with the wider reach of anaemia-focused treatment, illustrating how the size of a clinically defined subgroup affects revenue even when a therapy has clear differentiation.

 

Pipeline Competition Moves Beyond Basic JAK Inhibition

Development activity is shifting towards combinations and new mechanisms intended to deepen responses or improve outcomes after existing JAK inhibitors. Late-stage studies are also raising the evidence standard because spleen-volume improvement alone may not be sufficient for strong adoption.

Karyopharm’s Phase III SENTRY study evaluated selinexor with ruxolitinib in previously untreated patients. At week 24, 50% of combination-treated patients achieved at least a 35% reduction in spleen volume, compared with 28% receiving ruxolitinib alone. The trial met this co-primary endpoint but did not achieve a statistically significant advantage on its second co-primary symptom endpoint.

Grade 3 or higher adverse events occurred in 70% of combination-treated patients and 50% of the control group. Treatment discontinuation due to adverse events occurred in 15% and 9%, respectively. Regulatory discussions may continue, but tolerability and the missed symptom endpoint will affect the therapy’s competitive and payer positioning.

Pelabresib remains a prominent BET-inhibitor candidate. Earlier MANIFEST-2 findings supported its combination with frontline ruxolitinib, particularly for spleen responses. Novartis began another 460-patient Phase III study in June 2026, with completion expected in 2030. The programme remains strategically relevant, but the additional study extends its commercial timeline.

Geron’s imetelstat is being developed for patients whose disease has relapsed or become refractory after JAK-inhibitor therapy. The 320-patient Phase III IMpactMF trial is evaluating overall survival against best available therapy. A positive survival outcome would give the programme a stronger disease-modification position than treatments assessed mainly through spleen and symptom measures.

Bristol Myers Squibb’s Phase III INDEPENDENCE trial of luspatercept did not meet its primary endpoint of red-blood-cell transfusion independence for 12 consecutive weeks. Numerical improvements were reported in transfusion burden and haemoglobin-related measures, but the missed endpoint reduced the certainty of a near-term myelofibrosis indication.

Roginolisib remains an early Phase I/II combination programme with ruxolitinib in patients no longer responding adequately to JAK inhibition. Its limited enrolment places it behind late-stage competitors in commercial readiness.

Lilly’s April 2026 agreement to acquire Ajax Therapeutics for up to USD 2.3 billion adds investment to next-generation JAK2 development. Ajax’s AJ1-11095 is a Type II JAK2 inhibitor in Phase I development for patients previously treated with Type I JAK2 inhibitors. The transaction reflects strategic interest in post-JAK treatment, although clinical proof remains at an early stage.

 

Payer Gateways Decide Which Approvals Become Sales

Regulatory approval defines who may receive a treatment, while reimbursement determines how many patients can enter and remain in the treated market. NICE recommends momelotinib for adults with intermediate-2 or high-risk myelofibrosis, moderate-to-severe anaemia and either no previous JAK inhibitor or previous ruxolitinib therapy. Fedratinib is also available through NICE guidance, creating funded options within defined risk and treatment-history groups.

Australia’s Pharmaceutical Benefits Scheme illustrates the role of public subsidy in maintaining recurring demand. The continuing-treatment listing for momelotinib covers a 30-tablet pack with five repeats. As of July 2026, the published dispensed price for maximum quantity was A$5,882.90, while the general patient charge was A$25. Authority requirements restrict access, but reimbursement supports continuous monthly treatment for eligible patients.

Canada has issued a conditional reimbursement recommendation for momelotinib. The European Union has authorised Omjjara for adults with moderate-to-severe anaemia who are JAK-inhibitor naïve or previously treated with ruxolitinib. Revenue conversion across Europe depends on national pricing negotiations, formulary decisions and launch sequencing.

The United States remains the main commercial centre because of branded specialty-drug pricing, an identifiable patient population and established specialty-pharmacy distribution. Europe, Canada and Australia offer structured public access but apply stronger pricing and eligibility controls. Japan provides another concentrated opportunity, particularly within anaemic myelofibrosis.

 

Competitive Power Is Shifting Towards Cytopenic and Post-JAK Care

Incyte and Novartis retain the strongest established platform through ruxolitinib, supported by specialist familiarity, reimbursement and international distribution. GSK has gained momentum through momelotinib’s anaemia-focused positioning, while Sobi remains differentiated in severe thrombocytopenia despite revenue and pricing pressure. Bristol Myers Squibb continues to compete through fedratinib.

Pipeline competition includes Novartis in BET inhibition, Karyopharm in selinexor combinations, Geron in telomerase inhibition and Lilly through its planned acquisition of Ajax Therapeutics. These programmes are competing for patients who need longer responses, improved blood-count management or treatment after failure of an existing JAK inhibitor.

 

Myelofibrosis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.45 Billion
Revenue Forecast in 2032	USD 6.03 Billion
Overall Growth Rate	CAGR of 8.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Treatment Application, By End User, By Distribution Channel, By Geography
By Product Type	Ruxolitinib, Fedratinib, Pacritinib, Momelotinib, Other and Emerging Therapies
By Treatment Application	Anaemic Myelofibrosis, Severe Thrombocytopenic Myelofibrosis, JAK-Inhibitor-Naïve Myelofibrosis, Relapsed or Refractory Myelofibrosis
By End User	Hospitals, Haematology and Oncology Clinics, Specialty Treatment Centres, Homecare Settings
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of myeloproliferative disorders, increasing adoption of targeted JAK inhibitor therapies, growing demand for personalised treatment approaches, and expansion of haematology care infrastructure
Customization Option	Available upon request